Efficient Large-scale siRNA Manufacturing: Enzymatic Ligation of Short RNA Fragments
Linear synthesis by continuous-flow SPOS is the current state-of-the-art technology to manufacture oligonucleotide APIs. A very promising alternative, especially to manufacture large quantities, is the enzymatic ligation of short oligonucleotide fragments. This...
New trends in oligotherapeutics
The oligotherapeutics market has expanded in size, disease indications and exploratory molecules in recent years, As oligo API portfolios have grown more diverse, CDMOs are challenged to provide a toolbox of established and new synthesis, purification and scale-up...
Navigating regulatory affairs challenges for successful drugs
New drugs have to go through a long process of drug development before they reach the market. Along their manufacturing journey, many regulatory challenges arise that any successful drug has to pass in order to reach patients in a timely, safe and reliable manner....
Going Large-scale with Manufacturing of Oligonucleotides
The growing number of oligonucleotide-based APIs is accompanied by an increasing need for efficient routes for their large-scale manufacturing. It is therefore essential to develop more efficient, more sustainable, and highly scalable manufacturing techniques. The...